Abstract
Purpose
Advances in precision medicine (PM) have potential to reduce and/or eliminate breast cancer disparities in both treatment and survivorship. However, compared to white Americans, black Americans are often underrepresented in genetic research. This report assessed factors that influence receipt of buccal cells via saliva kits.
Methods
This prospective study recruited women with confirmed hormonal-positive (HR+) breast cancer (BC). A standardized telephone survey collected sociodemographic, socio-cultural (e.g., religiosity), and healthcare process factors. Clinical information was abstracted from medical records. After the baseline survey, return postage-paid envelopes and mouthwash collection kits were mailed. Univariate and adjusted logistic regression models estimated the probability of biospecimen donation.
Results
Seventy percent of the sample provided buccal cells which were of good quality. No differences were noted by race or other demographic factors. In the multivariable logistic model, time spent with providers (OR 1.61 per 1-point increase; 95% CI 1.242, 2.088) and religiosity (OR 0.957 per 1-point increase; 95% CI 0.931, 0.984) remained associated with biospecimen provision. Women with lower-stage cancer (vs. higher stage III+) were more likely to donate biospecimens (p < 0.05).
Conclusions
Cancer care experiences predicted specimen donation. Understanding the contextual reasons for lower receipt among women with higher religiosity scores and higher stage warrants further examination.
Implications for cancer survivors
PM is relevant to cancer survivors because of its potential to inform targeted therapies, understand disease resistance, and aide in prediction of toxicity and/or recurrence. Future efforts to launch precision medicine trials with BC survivors may benefit from engaging medical oncologists and/or leveraging patient-provider encounters for trial participation.
Similar content being viewed by others
References
American Cancer Society (2016) Cancer treatment & survivorship facts & figures 2016–2017.
DeSantis C, Ma J, Bryan L, et al. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64:52–62. https://doi.org/10.3322/caac.21203.
Wright JL, Reis IM, Zhao W, et al. Racial disparity in estrogen receptor positive breast cancer patients receiving trimodality therapy. Breast. 2012;21:276–83. https://doi.org/10.1016/j.breast.2011.11.003.
Ashley EA. The precision medicine initiative: a new national effort. JAMA. 2015;313:2119–20. https://doi.org/10.1001/jama.2015.3595.
McVeigh TP, Kerin MJ. Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer. Breast Cancer (Dove Med Press). 2017;9:393–400. https://doi.org/10.2147/BCTT.S109847.
National Cancer Institute (2015) Precision medicine initiative and cancer research.
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92. https://doi.org/10.1056/NEJM200103153441101.
Keenan T, Moy B, Mroz EA, et al. Comparison of the genomic landscape between primary breast cancer in African American versus white women and the association of racial differences with tumor recurrence. J Clin Oncol. 2015;33:3621–7. https://doi.org/10.1200/JCO.2015.62.2126.
Bast RC Jr, Hortobagyi GN. Individualized care for patients with cancer—a work in progress. N Engl J Med. 2004;351:2865–7.
Ramirez J, Elmofty M, Castillo E, et al. Evaluation of cortisol and telomere length measurements in ethnically diverse women with breast cancer using culturally sensitive methods. J Community Genet. 2017;8:75–86. https://doi.org/10.1007/s12687-016-0288-y.
Khoury MJ, Yang Q, Gwinn M, et al. An epidemiologic assessment of genomic profiling for measuring susceptibility to common diseases and targeting interventions. Genet Med. 2004;6:38–47. https://doi.org/10.1097/01.GIM.0000105751.71430.79.
Roselli M, Ferroni P, Riondino S, et al. Functional impairment of activated protein C in breast cancer—relationship to survival outcomes. Am J Cancer Res. 2016;6:1450–7.
Henry NL, Bedard PL, DeMichele A. Standard and genomic tools for decision support in breast cancer treatment. Am Soc Clin Oncol Educ Book. 2017;37:106–15. 10.14694/EDBK_175617.
Jones T, Lockhart JS, Mendelsohn-Victor KE, et al. Use of cancer genetics services in African-American young breast cancer survivors. Am J Prev Med. 2016;51:427–36. https://doi.org/10.1016/j.amepre.2016.03.016.
Ford JG, Howerton MW, Lai GY, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer. 2008;112:228–42. https://doi.org/10.1002/cncr.23157.
Scott EA, Schlumpf KS, Mathew SM, et al. Biospecimen repositories: are blood donors willing to participate? Transfusion. 2010;50:1943–50.
Levy DE, Byfield SD, Comstock CB, et al. Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk. Genet Med. 2011;13:349–55. https://doi.org/10.1097/GIM.0b013e3182091ba4.
Kwiatkowski K, Coe K, Bailar JC, et al. Inclusion of minorities and women in cancer clinical trials, a decade later: have we improved? Cancer. 2013;119:2956–63. https://doi.org/10.1002/cncr.28168.
Dash C, Wallington SF, Muthra S, et al. Disparities in knowledge and willingness to donate research biospecimens: a mixed-methods study in an underserved urban community. J Community Genet. 2014;5:329–36. https://doi.org/10.1007/s12687-014-0187-z.
McDonald JA, Weathers B, Barg FK, Troxel AB, Shea JA, Bowen HCH. Provision intentions for cancer genetics research among African Americans. Genetic testing and molecular biomarkers. 2012;16(4):252–8.
Loffredo CA, Luta G, Wallington S, et al. Knowledge and willingness to provide research biospecimens among foreign-born Latinos using safety-net clinics. J Community Health. 2013;38:652–9. https://doi.org/10.1007/s10900-013-9660-6.
Hagiwara N, Berry-Bobovski L, Francis C, et al. Unexpected findings in the exploration of African American underrepresentation in biospecimen collection and biobanks. J Cancer Educ. 2014;29:580–7. https://doi.org/10.1007/s13187-013-0586-6.
Adams-Campbell LL, Dash C, Palmer JR, et al. Predictors of biospecimen donation in the black women’s health study. Cancer Causes Control. 2016;27:797–803. https://doi.org/10.1007/s10552-016-0747-0.
Morrison DG, Farah C, Hock JM. Informed consent for biobanking research: cancer patient recruitment from rural communities in Maine. Biopreserv Biobank. 2013;11:107–14. https://doi.org/10.1089/bio.2012.0054.
Kwan PP, Briand G, Lee C, et al. Use of a community-based participatory research approach to assess knowledge, attitudes, and beliefs on biospecimen research among Pacific Islanders. Health Promot Pract. 2014;15:422–30. https://doi.org/10.1177/1524839913516464.
Drake BF, Boyd D, Carter K, et al. Barriers and strategies to participation in tissue research among African-American men. J Cancer Educ. 2017;32:51–8. https://doi.org/10.1007/s13187-015-0905-1.
Dang JH, Rodriguez EM, Luque JS, et al. Engaging diverse populations about biospecimen donation for cancer research. J Community Genet. 2014;5:313–27. https://doi.org/10.1007/s12687-014-0186-0.
Tong EK, Fung LC, Stewart SL, et al. Impact of a biospecimen collection seminar on willingness to donate biospecimens among Chinese Americans: results from a randomized, controlled community-based trial. Cancer Epidemiol Biomark Prev. 2014;23:392–401. https://doi.org/10.1158/1055-9965.EPI-13-0744.
Braun KL, Tsark JU, Powers A, et al. Cancer patient perceptions about biobanking and preferred timing of consent. Biopreserv Biobank. 2014;12:106–12. https://doi.org/10.1089/bio.2013.0083.
Brady MJ, Cella DF, Mo F, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol. 1997;15:974–86.
GN M, RD H (1994) The patient satisfaction questionnaire short-form (PSQ-18), P-7865.
LaVeist TA, Isaac LA, Williams KP. Mistrust of health care organizations is associated with underutilization of health services. Health Serv Res. 2009;44:2093–105.
Roth AJ, Kornblith AB, Batel-Copel L, et al. Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study. Cancer. 1998;82:1904–8. https://doi.org/10.1002/(SICI)1097-0142(19980515)82:103.0.CO;2-X.
Venetis MK, Robinson JD, Turkiewicz KL, et al. An evidence base for patient-centered cancer care: a meta-analysis of studies of observed communication between cancer specialists and their patients. Patient Educ Couns. 2009;77:379–83. https://doi.org/10.1016/j.pec.2009.09.015.
Sheppard VB, Wallington SF, Wiley S, et al. A peer-led decision support intervention improves decision outcomes in black women with breast cancer. J Cancer Educ. 2013;28:262–9.
Eggly S, Barton E, Winckles A, et al. A disparity of words: racial differences in oncologist-patient communication about clinical trials. Health Expect. 2015;18:1316–26. https://doi.org/10.1111/hex.12108.
Byrd GS, Edwards CL, Kelkar VA, et al. Recruiting intergenerational African American males for biomedical research studies: a major research challenge. J Natl Med Assoc. 2011;103:480–7.
Kiviniemi MT, Saad-Harfouche FG, Ciupak GL, et al. Pilot intervention outcomes of an educational program for biospecimen research participation. J Cancer Educ. 2013;28:52–9.
Dash C, Wallington S, Muthra S, et al. Disparities in knowledge and willingness to donate research biospecimens: a mixed-methods study in an underserved urban community. J Community Genet. 2014 Oct;5:329–36.
Partridge EE. Yes, minority and underserved populations will participate in biospecimen collection. Cancer Epidemiol Biomark Prev. 2014;23:895–7. https://doi.org/10.1158/1055-9965.EPI-14-0018.
Townsend CK, Dillard A, Hosoda KK, et al. Community-based participatory research integrates behavioral and biological research to achieve health equity for native Hawaiians. Int J Environ Res Public Health. 2015;13:ijerph13010004. https://doi.org/10.3390/ijerph13010004.
Acknowledgements
The authors are grateful to study participants who took the time to participate in this study. Additionally, we appreciate the diligence of study research assistants Ms. Minna Song and Ms. Themis Elian who helped recruit, consent, and interview women. We also appreciate technical assistance from Dr. Arnethea Sutton and Ms. Megan Edmonds, MPH. Funded by Georgetown-Howard Universities Center for Clinical and Translational Science (GHUCCTS) by Federal Funds, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), through the Clinical and Translational Science Awards Program (CTSA) (Hurtado de Mendoza: KL2TR001432).
Funding
This research was funded by the National Institutes of Health R01CA154848 (Sheppard) and R01 CA132996 (Zheng). It was also supported in part by the NIH-NCI Cancer Center Support Grant P30 CA016059, Nontherapeutic Subject Registry Shared Resource at Lombardi Comprehensive Cancer Center under NCI Grant: NTSR P30 CA51008, and the Laboratory of Telomere Health P30 CA51008.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Sheppard, V.B., Hurtado-de-Mendoza, A., Zheng, YL. et al. Biospecimen donation among black and white breast cancer survivors: opportunities to promote precision medicine. J Cancer Surviv 12, 74–81 (2018). https://doi.org/10.1007/s11764-017-0646-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11764-017-0646-8